RDHL Redhill Biopharma
- 0.465
- +0.007+1.46%
Redhill Biopharma News
RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035
RedHill Biopharma Ltd. (NASDAQ:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced the issue of a new Chinese patent Notice of Allowance covering opaganib[1] as
RedHill Biopharma Advances COVID-19 Antiviral Study
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Of RHB-107 (Upamostat), The Study Is Expected To Be Completed By The End Of 2024
RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study Of RHB-107 (Upamostat), The Study Is Expected To Be Completed By The End Of 2024
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (Vs US$46.29 Loss in FY 2022)
RedHill Biopharma's Strategic Pivot and Financial Turnaround
RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights
Selected for evaluation by two U.S. government countermeasures programs for Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure.
RedHill Biopharma FY23 EPS $0.01 Up From $(0.12) YoY Revenue $6.5M Down From $61.8M YoY
RedHill Biopharma FY23 EPS $0.01 Up From $(0.12) YoY Revenue $6.5M Down From $61.8M YoY
RedHill Biopharma 2023 Rev $6.5M >RDHL
RedHill Biopharma 2023 Rev $6.5M >RDHL
RedHill Biopharma Secures $1.25M in Direct Offering
RedHill Biopharma Announces Securities Sale
RedHill BiopharmaJazz Pharmaceuticals Completes Zanidatamab Biologics License Application For Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
RedHill BiopharmaJazz Pharmaceuticals Completes Zanidatamab Biologics License Application For Previously Treated HER2-Positive Metastatic Biliary Tract Cancer
RedHill Biopharma Announces $1.25M Registered Direct Offering at a Premium to Market Price
RedHill Biopharma Announces $1.25M Registered Direct Offering at a Premium to Market Price
RedHill Biopharma Share Capital Increase Approved
RedHill Biopharma Reschedules Shareholders Meeting
RedHill Biopharma Receives New Patent For H. Pylori Treatment Talicia
Redhill Biopharma Announced Issue Of New U.S. Patent Covering Talicia As An All-in-one Fixed-dose Combination Of Amoxicillin, Omeprazole And Rifabutin And Its Use For Helicobacter Pylori; Expected To Provide Protection For Talicia Until Feb 12, 2034
Redhill Biopharma Announced Issue Of New U.S. Patent Covering Talicia As An All-in-one Fixed-dose Combination Of Amoxicillin, Omeprazole And Rifabutin And Its Use For Helicobacter Pylori; Expected To
Redhill Biopharma And Apogee Biotechnology's Opaganib Selected By U.S. Government's Chemical Medical Countermeasures Program And Chemical Countermeasures Research Program For A Potential Medical Countermeasure Against Inhalation Sulfur Mustard Exposure
Redhill Biopharma And Apogee Biotechnology's Opaganib Selected By U.S. Government's Chemical Medical Countermeasures Program And Chemical Countermeasures Research Program For A Potential Medical Count
RedHill Biopharma Will Be Issued U.S. Patent Number 11,918,560 Tomorrow Titled "Serine Protease Inhibitor For Treating Coronavirus Infection"
RedHill Biopharma Will Be Issued U.S. Patent Number 11,918,560 Tomorrow Titled "Serine Protease Inhibitor For Treating Coronavirus Infection"
RedHill Biopharma Says Published Data Shows That Opaganib Protects Against Radiation-induced Lung Inflammation And Fibrosis In An In Vivo Mouse Model Of Lung Damage Following Exposure To Ionizing Radiation
RedHill Biopharma Says Published Data Shows That Opaganib Protects Against Radiation-induced Lung Inflammation And Fibrosis In An In Vivo Mouse Model Of Lung Damage Following Exposure To Ionizing Radi
Analysis
Price Target
No Data
